These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 35696544)

  • 1. Cost-effectiveness of Coronavirus Disease 2019 Vaccination in Low- and Middle-Income Countries.
    Siedner MJ; Alba C; Fitzmaurice KP; Gilbert RF; Scott JA; Shebl FM; Ciaranello A; Reddy KP; Freedberg KA
    J Infect Dis; 2022 Nov; 226(11):1887-1896. PubMed ID: 35696544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study.
    Savinkina A; Bilinski A; Fitzpatrick M; Paltiel AD; Rizvi Z; Salomon J; Thornhill T; Gonsalves G
    BMJ Open; 2022 Sep; 12(9):e061752. PubMed ID: 36100306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    Pearson CAB; Bozzani F; Procter SR; Davies NG; Huda M; Jensen HT; Keogh-Brown M; Khalid M; Sweeney S; Torres-Rueda S; ; ; Eggo RM; Vassall A; Jit M
    PLoS Med; 2021 Oct; 18(10):e1003815. PubMed ID: 34606520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the impacts of COVID-19 vaccination programme's timing and speed on health benefits, cost-effectiveness, and relative affordability in 27 African countries.
    Liu Y; Procter SR; Pearson CAB; Montero AM; Torres-Rueda S; Asfaw E; Uzochukwu B; Drake T; Bergren E; Eggo RM; Ruiz F; Ndembi N; Nonvignon J; Jit M; Vassall A
    BMC Med; 2023 Mar; 21(1):85. PubMed ID: 36882868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation.
    Fu H; Abbas K; Malvolti S; Gregory C; Ko M; Amorij JP; Jit M
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 37949503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disparities and effectiveness of COVID-19 vaccine policies in three representative European countries.
    Xie W; Shi L; Liu M; Yang J; Ma M; Sun G
    Int J Equity Health; 2024 Jan; 23(1):16. PubMed ID: 38287322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya.
    Orangi S; Ojal J; Brand SP; Orlendo C; Kairu A; Aziza R; Ogero M; Agweyu A; Warimwe GM; Uyoga S; Otieno E; Ochola-Oyier LI; Agoti CN; Kasera K; Amoth P; Mwangangi M; Aman R; Ng'ang'a W; Adetifa IM; Scott JAG; Bejon P; Keeling MJ; Flasche S; Nokes DJ; Barasa E
    BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35914832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study.
    Clark RA; Mukandavire C; Portnoy A; Weerasuriya CK; Deol A; Scarponi D; Iskauskas A; Bakker R; Quaife M; Malhotra S; Gebreselassie N; Zignol M; Hutubessy RCW; Giersing B; Jit M; Harris RC; Menzies NA; White RG
    Lancet Glob Health; 2023 Apr; 11(4):e546-e555. PubMed ID: 36925175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.
    So AD; Woo J
    BMJ; 2020 Dec; 371():m4750. PubMed ID: 33323376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
    Patel HD; Roberts ET; Constenla DO
    Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries.
    Duroseau B; Kipshidze N; Limaye RJ
    Front Public Health; 2022; 10():1087138. PubMed ID: 36711400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries.
    Ma S; Lavelle TA; Ollendorf DA; Lin PJ
    Appl Health Econ Health Policy; 2022 May; 20(3):395-404. PubMed ID: 35001292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
    Watson OJ; Barnsley G; Toor J; Hogan AB; Winskill P; Ghani AC
    Lancet Infect Dis; 2022 Sep; 22(9):1293-1302. PubMed ID: 35753318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination.
    Bartsch SM; Wedlock PT; O'Shea KJ; Cox SN; Strych U; Nuzzo JB; Ferguson MC; Bottazzi ME; Siegmund SS; Hotez PJ; Lee BY
    J Infect Dis; 2021 Sep; 224(6):938-948. PubMed ID: 33954775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries.
    Obeng-Kusi M; Habila MA; Roe DJ; Erstad B; Abraham I
    J Med Econ; 2021 Nov; 24(sup1):1-13. PubMed ID: 34866541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.
    Rheingans R; Atherly D; Anderson J
    Vaccine; 2012 Apr; 30 Suppl 1():A15-23. PubMed ID: 22520124
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.